Soligenix initiates phase 2 clinical trial of sgx302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis

Study hpn-psr-01 opens patient enrollment princeton, n.j. , dec. 19, 2022 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that patient enrollment has been opened for its phase 2a study (protocol number hpn-psr-01) evaluating sgx302 (synthetic hypericin) in the treatment of mild-to-moderate psoriasis.
SNGX Ratings Summary
SNGX Quant Ranking